文章摘要
韦灵玉,邱晓春,周彦来,王作荣.PDCA循环管理在医院药品不良反应监测工作中的应用[J].中国药事,2017,(6):703-710
PDCA循环管理在医院药品不良反应监测工作中的应用
Application of PDCA Cycle Management in Monitoring ADR in Hospital
投稿时间:2016-09-18  
DOI:10.16153/j.1002-7777.2017.06.022
中文关键词: PDCA循环  药品不良反应  医疗质量管理  监测  骨髓抑制  合理用药
英文关键词: PDCA cycle  ADR  medical quality management  monitoring  bone marrow suppression  rational drug use
基金项目:
作者单位E-mail
韦灵玉 贵州省肿瘤医院, 贵阳 550001  
邱晓春 贵州省肿瘤医院, 贵阳 550001 chunqiu218@126.com 
周彦来 贵州省肿瘤医院, 贵阳 550001  
王作荣 贵州省肿瘤医院, 贵阳 550001  
摘要点击次数: 1107
全文下载次数: 562
中文摘要:
      目的:探讨医疗单位药品不良反应(ADR)报告监测管理办法,提高ADR报告和监测管理质量,促进医院安全、合理用药。方法:运用PDCA循环医疗质量管理办法,分析贵州省肿瘤医院2011-2015年ADR监测情况,提出持续改进措施,促进我院安全、合理用药。结果:我院5年上报ADR数量为1363例,其中运用PDCA管理方法前(2011年)有效例数仅为47例,实施PDCA循环管理后2012-2015年ADR有效例数分别为171、286、417、442例,报告总例数逐年升高;2011-2015年严重的ADR报告例数分别为0(占0.00%)、58(占33.92%)、142(占49.65%)、118(占28.30%)、172(占38.91%)例;有效报表的比例从2011年的82.46%上升到2015年100.00%;对比实施管理前我院ADR报告的品种和数量明显增多,以抗肿瘤及其辅助用药为主,占57.45%;2011-2015年抗肿瘤药物引发的严重ADR累及系统以红细胞异常为主,占68.67%。结论:运用PDCA循环和质量管理工具,坚持计划、实施、检查、处理循序渐进,能有效提高ADR监测管理水平,最大程度地减低风险、保证患者用药安全。
英文摘要:
      Objective: To explore the monitoring management measures for ADR reports in hospital, so as to improve the quality of monitoring and management of ADR reports, and to promote safe and rational drug use. Methods: The monitoring status of ADR from 2011 to 2015 in Guizhou Provincial Tumor Hospital was analyzed and continuous improvement measures were put forward so as to promote safe and rational drug use by using PDCA cycle management of medical quality. Results: A total of 1363 ADR cases had been reported in the past 5 years; only 47 cases were reported in 2011 before implementation of PDCA cycle management, whereas 171, 286, 417, 442 cases were reported respectively from 2012 to 2015 after implementation of PDCA cycle management. The total number of reported cases increased year by year. The total numbers of serious ADR reports from 2011 to 2015 were 0(0.00%), 58(33.92%), 142(49.65%), 118(28.30%), 172(38.91%) respectively.The rate of valid reports increased from 82.46% to 100.00%. The variety and quantity of ADRs significantly increased compared with those in 2011. Majority of ADRs were antitumor drugs and adjuvant drugs (57.45%). As far as the ADR involved systems were concerned, the severe ADR caused by antitumor drugs in 2011-2015 was abnormal RBC (68.67%). Conclusion: Using PDCA cycle and quality management tools, and adhering to the plan, implementation, inspection and step-by-step processing can effectively improve the quality of ADR monitoring management level, reduce risks and ensure the patients safety with drug use to the greatest extent.
查看全文   查看/发表评论  下载PDF阅读器
关闭